1-6 of 6
Joshua E. Allen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

ONC201 Shows Potent Anticancer Activity Against Medullary Thyroid Cancer via Transcriptional Inhibition of RET, VEGFR2, and IGFBP2

Rozita Bagheri-Yarmand, Ramona Dadu, Lei Ye, Yaashmin Shiny Jebaraj, Jade A. Martinez, Junsheng Ma, Rohinton S. Tarapore, Joshua E. Allen, Steven I. Sherman, Michelle D. Williams, Robert F. Gagel
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (4): 665–675.
https://doi.org/10.1158/1535-7163.MCT-20-0386
Published: 01 April 2021
View article titled, ONC201 Shows Potent Anticancer Activity Against Medullary Thyroid Cancer via Transcriptional Inhibition of <em>RET</em>, <em>VEGFR2</em>, and <em>IGFBP2</em>
Open the PDF for ONC201 Shows Potent Anticancer Activity Against Medullary Thyroid Cancer via Transcriptional Inhibition of <em>RET</em>, <em>VEGFR2</em>, and <em>IGFBP2</em> in another window
Journal Articles

Abstract B130: Differentiated pharmacology of the imipridone ONC201: the first selective DRD2/3 antagonist in clinical oncology

Neel S. Madhukar, Varun Vijay Prabhu, Lakshmi Anantharaman, Chidananda Sulli, Edgar Davidson, Sean Deacon, Joseph Rucker, Neil Charter, Benjamin Doranz, Wolfgang Oster, Olivier Elemento, R. Benjamin Free, David Sibley, Joshua E. Allen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): B130.
https://doi.org/10.1158/1535-7163.TARG-17-B130
Published: 01 January 2018
View article titled, Abstract B130: Differentiated pharmacology of the imipridone ONC201: the first selective DRD2/3 antagonist in clinical oncology
Journal Articles

Abstract A060: Targeting DRD2 dysregulation in recurrent glioblastoma with imipridone ONC201: predictive and pharmacodynamic clinical biomarker analyses

Varun Vijay Prabhu, Neel Madhukar, C. Leah B. Kline, Rohinton Tarapore, Wafik El-Deiry, Olivier Elemento, Faye Doherty, Alexander VanEngelenburg, Jessica Durrant, Andrew Zloza, Cyril Benes, Isabel Arrillaga, Wolfgang Oster, Joshua E. Allen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): A060.
https://doi.org/10.1158/1535-7163.TARG-17-A060
Published: 01 January 2018
View article titled, Abstract A060: Targeting DRD2 dysregulation in recurrent glioblastoma with imipridone ONC201: predictive and pharmacodynamic clinical biomarker analyses
Journal Articles

Abstract LB-A16: Novel Small Molecule ONC201 Induces Cell Death in Triple Negative and Non-triple Negative Breast Cancer Cells

Marie D. Baumeister, Jessica Wagner, Christina L.B. Kline, Joshua E. Allen, David T. Dicker, Wafik S. El-Deiry
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): LB-A16.
https://doi.org/10.1158/1535-7163.TARG-15-LB-A16
Published: 01 December 2015
View article titled, Abstract LB-A16: Novel Small Molecule ONC201 Induces Cell Death in Triple Negative and Non-triple Negative Breast Cancer Cells
Journal Articles

Sangivamycin-like Molecule 6 Exhibits Potent Anti-Multiple Myeloma Activity through Inhibition of Cyclin-Dependent Kinase-9

Nathan G. Dolloff, Joshua E. Allen, David T. Dicker, Nicole Aqui, Dan Vogl, Jozef Malysz, Giampaolo Talamo, Wafik S. El-Deiry
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (11): 2321–2330.
https://doi.org/10.1158/1535-7163.MCT-12-0578
Published: 08 November 2012
View article titled, Sangivamycin-like Molecule 6 Exhibits Potent Anti-Multiple Myeloma Activity through Inhibition of Cyclin-Dependent Kinase-9
Open the PDF for Sangivamycin-like Molecule 6 Exhibits Potent Anti-Multiple Myeloma Activity through Inhibition of Cyclin-Dependent Kinase-9 in another window
Includes: Supplementary data
Journal Articles

Targeting TRAIL Death Receptor 4 with Trivalent DR4 Atrimer Complexes

Joshua E. Allen, Roger Ferrini, David T. Dicker, Glenda Batzer, Elise Chen, Daniela I. Oltean, Bing Lin, Mark W. Renshaw, Anke Kretz-Rommel, Wafik S. El-Deiry
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (10): 2087–2095.
https://doi.org/10.1158/1535-7163.MCT-12-0366
Published: 09 October 2012
View article titled, Targeting TRAIL Death Receptor 4 with Trivalent DR4 Atrimer Complexes
Open the PDF for Targeting TRAIL Death Receptor 4 with Trivalent DR4 Atrimer Complexes in another window
Includes: Supplementary data